Docetaxel e Nuove Strategie di Trattamento del NSCLC

NSCLC Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ, 311: 899–909, 1995.

Mattson K.V. , Abratt R.P. , ten Velde G. , Krofta K. : Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol, 14: 116–122, 2003.

Betticher D.C. , Hsu Schmitz S.F. , Totsch M. : Mediastinal lymph node clearance after docetaxelcisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol, 21: 1752–1759, 2003.

Kim T.Y. , Yang S.H. , Lee S.H. : A phase III randomized trial of combined CT/RT vs RT alone in locally advanced NSCLC. Am J Clin Oncol, 25: 238–243, 2002.

Sause W. , Kolesar P. , Taylor S. : Final results of phase III trial in regionally advanced unresectable NSCLC: RTOG, ECOG and SWOG. Chest, 117: 358–364, 2000.

Sim S. , Rosenzweig K.E. , Schindelheim R. : Induction CT plus three-dimensional conformai RT in the definitive treatment of locally advanced NSCLC. Int J Radiat Oncol Biol Phys, 51: 660–665, 2001.

Dillman R.O. , Herndon J. , Seagren S.L. : Improved survival in stage III NSCLC: seven-year follow-up of CALGB 8433 trial. J Natl Cancer Inst, 88: 1210–1215, 1996.

Chemotherapy for NSCLC: NSCLC collaborative group. Cochrane Database of Systematic Reviews: CD002139, 2000.

Curran W.J. , Scott C. , Langer C. : Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III NSCLC: initial report of a RTOG 9410 trial. Proc ASCO, 19: abst 1891, 2000.

Furuse K. , Fukuoka M. , Kawahara M. : Phase III of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III NSCLC. J Clin Oncol, 17: 2692–2699, 1999.

Vokes E.E. , Herndon J.E. , Kelley M.J. : Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): initial analysis of a randomized phase III trial. Proc ASCO, 23: abst 7005, 2004.

Gandara D.R. , Chansky K. , Albain K. : Consolidation docetaxel after concurrent CT/RT in stage IIIB NSCLC: phase II SWOG study S 9504. J Clin Oncol, 21: 2004–2010, 2003.

Albain K.S. , Crowley J.J. , Turrisi A.T. : Concurrent cisplatin, etoposide plus RT for pathologic stage IIIB NSCLC: a SWOG phase II study S 9019. J Clin Oncol, 20: 3454–3460, 2002.

Lara P. , Chanski K. , Gaspar L. : Consolidation docetaxel following concurrent CT/RT in stage III NSCLC: updated five-years survival results from SWOG trial S9504. Proc IASLC 2005, abst PD-075.

Kelly K. , Gaspar L.E. , Chansky K. : Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and gefitinib/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. Proc ASCO, 24: abst 7058, 2005.

Schiller J.H. , Harrington D. , Belani C.P. : Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. NEJM, 346: 92–98, 2002.

Fossella F. , Pereira J.R. , von Pawel J. : Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced NSCLC: the TAX 326 study group. J Clin Oncol, 21: 3016–3024, 2003.

Gralla R.J. , Rodrigues J. , von Pawel J. : Prospective analysis of quality of life in a randomized multinational phase III study comparing docetaxel plus either cisplatin or carboplatin with vinorelbine plus cisplatin in patients with advanced NSCLC. Proc ASCO, 21: 300a, 2002.

Fossella F. , Belani C. for the TAX 326 Study Group: Phase III study (TAX 326) of docetaxelcisplatin and docetaxel-carboplatin versus vinorelbine-cisplatin for the first-line treatment of advanced/metastatic NSCLC: analysis in elderly patients. Proc ASCO, 22: abst 2528, 2003.

Mendelsohn J. , Baselga J. : Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol, 21: 2787–2799, 2003.

Paez J.G. , Janne P.A. , Lee J.C. : EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304: 1497–1500, 2004.

Fanucchi M.P. , Fossella F. , Fidias P. : Bortezomib ± docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a phase 2 study. Proc ASCO, 24: abst 7034, 2005.

Hida T. , Kozaki K. , Muramatsu H. : Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res, 6: 2006–2011, 2000.

Gadgeel S.M. , Thatai L. , Kraut M. : Phase II study of celecoxib and docetaxel in NSCLC patients with progression after platinum-based therapy. Proc ASCO, 22: abst 2749, 2003.

Nugent F.W. , Graziano S. , Levitan N. : Docetaxel and COX-2 inhibition with celecoxib in relapsed/refractory NSCLC: promising progression-free survival in a phase II study. Proc ASCO, 22: abst 2697, 2003.

Chaplen R.A. , Kalemkerian G.P. , Wozniak N. : Celecoxib and weekly docetaxel in elderly or PS2 patients with advanced NSCLC. Proc ASCO, 23: abst 7102, 2004.

Underhill C. , Hui R. , Links M. : Phase II study of docetaxel plus celecoxib as first or second line therapy in patients with advanced NSCLC. Proc IASLC, abst P-586, 2005.

Gumerlock P.H. , Pryde B.J. , Kimura T. : Enhanced cytotoxicity of docetaxel + OSI-774 combination in NSCLC. Proc ASCO, 22: abst 2661, 2003.

Davies A.M. , Lara P.N. , Lau T. : Intermittent erlotinib in combination with docetaxel: phase I schedules designed to achieve pharmacodynamic separation. J Clin Oncol, 24: 630s (abst 7038), 2005.

Fandi A. , Gatzemeier U. , Smith R. : Final data from a pilot trial of gefitinib (ZD1839) in combination with docetaxel in patients with advanced or metastatic NSCLC: safely and pharmacokinetics. Proc ASCO, 22: abst 2635, 2003.

Bepler G. , Williams C.C. , Chiapponi A. : Docetaxel and gefitinib in the first-line treatment of elderly patients (≥70) with advanced non-small cell lung cancer (ANSCLC): results of phase II trial. Proc ASCO, 24: abst 7155, 2005.

Stinchcombe T. , Socinski M. , Choksi J. : A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV NSCLC. Proc IASLC, abst P-576, 2005.

Kim E.S. , Mauer A.M. , Tran H.T. : A phase II study of cetuximab, an EGFR-blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced NSCLC: final report. Proc ASCO, 22: abst 2581, 2003.

Herbst R. , Johnson B. , Rowbottom J. : ZD6474 plus docetaxel in patients with previously treated NSCLC: results of a randomized, placebo-controlled phase II trial. Proc IASLC, abst O-100, 2005.

Cunningham C. , Richards D. , Salgia R. : Phase 2 trial of talabostat and docetaxel in patients with stage IIIb/IV NSCLC. Proc ASCO, 24: abst 7120, 2005.

Reed E. : Platinum-DNA adduct, nucleotide excision repair and platinum based anticancer chemotherapy. Cancer Treat Rev, 24: 331–344, 1998.

Chaney S.G. , Sancar A. : DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst, 88: 1346–1360, 1996.

Dabholkar M. , Vionnet J. , Bostik-Bruton F. : Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Investig, 94: 703–708, 1994.

Metzger R. , Leichman C.G. , Danenberg K.D. : ERCC1 mRNA levels complement thymidilate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol, 16: 309–316, 1998.

Yang L. , Yi L. , Jiang H. : Expression of ERCC1 antisense mRNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res, 6: 773–781, 2000.

Lord R.V. , Brabender J. , Gandara D. : Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in NSCLC. Clin Cancer Res, 8: 2286–2291, 2002.

Roseli R. , Cobo M. , Isla B. : ERCC1 mRNA-based randomized phase III trial of docetaxel doublets with cisplatin or gemcitabine in stage IV NSCLC patients. Proc ASCO, 24: abst 7002, 2005.